HTG Molecular Diagnostics Total Revenue

HTG Molecular Diagnostics (HTGM) currently reports a total revenue of $6.2M as of March 2023. That compares with $8.7M in the prior-year period — down 28.2% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore HTG Molecular Diagnostics's total revenue history and peer comparisons.

HTG Molecular Diagnostics's total revenue decreased from $8.7M to $6.2M — a 28.2% year-over-year decrease (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

HTG Molecular Diagnostics's total revenue of $6.2M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

HTG Molecular Diagnostics reported $6.2M in total revenue as of March 2023. That compares with $8.7M in the prior-year period — down 28.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $6.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for HTG Molecular Diagnostics, and consider following HTGM for alerts when major investors trade the stock.